Hitoshi Kusaba
Overview
Explore the profile of Hitoshi Kusaba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanoue K, Ohmura H, Uehara K, Ito M, Yamaguchi K, Tsuchihashi K, et al.
Nat Commun
. 2024 Oct;
15(1):9033.
PMID: 39426955
Despite the success of immune checkpoint blockade (ICB) therapy for esophageal squamous cell cancer, the key immune cell populations that affect ICB efficacy remain unclear. Here, imaging mass cytometry of...
2.
Furukawa K, Ohmura H, Moriyama S, Uehara K, Ito M, Tsuchihashi K, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):113-122.
PMID: 39385509
Background: Malignant primary cardiac tumors require multimodal approaches including surgery, chemotherapy and radiotherapy, but these treatments can be associated with cardiovascular complications. However, few reports have described the cardiovascular complications...
3.
Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, et al.
BMC Cancer
. 2023 Oct;
23(1):1046.
PMID: 37904096
Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the...
4.
Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, et al.
Cancer Immunol Immunother
. 2023 Aug;
72(11):3543-3558.
PMID: 37550428
Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The...
5.
Nakano M, Taguchi R, Kikushige Y, Isobe T, Miyawaki K, Mizuno S, et al.
Cancer Sci
. 2023 Mar;
114(7):2895-2906.
PMID: 36945114
The cancer stem cell (CSC) theory features typically rare self-renewing subpopulations that reconstitute the heterogeneous tumor. Identification of molecules that characterize the features of CSCs is a key imperative for...
6.
Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy
Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al.
Open Heart
. 2023 Jan;
9(2).
PMID: 36600585
Background: Cancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin-angiotensin system inhibitor (RASI) may have a...
7.
Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al.
Circ J
. 2022 Dec;
88(2):217-225.
PMID: 36476830
Background: Hypertension is a frequent adverse event caused by vascular endothelial growth factor signaling pathway (VSP) inhibitors. However, the impact of hypertension on clinical outcomes during VSP inhibitor therapy remains...
8.
Ura T, Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, et al.
Esophagus
. 2022 Nov;
20(2):272-280.
PMID: 36427158
Background: We herein investigated the association between early tumor shrinkage (ETS) and depth of response (DpR) and clinical outcomes in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined...
9.
Yoshihiro T, Ariyama H, Yamaguchi K, Imajima T, Yamaga S, Tsuchihashi K, et al.
Cancer Sci
. 2022 Sep;
113(12):4207-4218.
PMID: 36053154
Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies...
10.
Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, et al.
Jpn J Clin Oncol
. 2022 Sep;
52(12):1416-1422.
PMID: 36047806
Background: Patients with cancer of unknown primary site are divided into two distinct groups, favourable and unfavourable subsets. For the unfavourable subset, empiric treatment or site-specific treatment is recommended, but...